Study #2017-0193
Feasibility Trial Of Pembrolizumab In Unresectable Thymoma And Thymic Carcinoma
MD Anderson Study Status
Enrolling
Treatment Agent
Pembrolizumab
Description
This phase I trial studies the sides effects and best dose of pembrolizumab in treating participants with thymoma or thymic cancer that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Stage III Thymoma AJCC V8, Stage IIIA Thymoma AJCC V8, Stage IIIB Thymoma AJCC V8, Stage IV Thymoma AJCC V8, Stage IVA Thymoma AJCC V8, Stage IVB Thymoma AJCC V8, Unresectable Thymic Carcinoma
Study phase:
Phase I
Physician name:
Anne Tsao
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-844-955-5036
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.